Baseline factors influential on ASAS 20 response in ankylosing spondylitis patients treated with etanercept (ENBREL®)

被引：0
|
作者：
Davis, JC
van der Heijde, DM
Dougados, M
Braun, J
Cush, JJ
Clegg, DO
Inman, RD
Devries, T
Tsuji, WH
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Hosp Masstricht, Maastricht, Netherlands
[3] Hosp Cochin, Paris, France
[4] Rheumazentrum Ruhrgebiet, Herne, Germany
[5] Presbyterian Med Ctr, Dallas, TX USA
[6] Univ Utah, Ctr Med, Salt Lake City, UT USA
[7] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada
[8] Amgen Inc, Thousand Oaks, CA USA
来源：
ARTHRITIS AND RHEUMATISM | 2003年 / 48卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1097
引用
收藏
页码：S440 / S440
页数：1
相关论文
共 50 条
  • [1] Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept
    Davis, JC
    van der Heijde, DMFM
    Dougados, M
    Braun, J
    Cush, JJ
    Clegg, DO
    Inman, RD
    de Vries, T
    Tsuji, WH
    [J]. JOURNAL OF RHEUMATOLOGY, 2005, 32 (09) : 1751 - 1754
  • [2] Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics
    Stone, MA
    Inman, RD
    Wright, JG
    Maetzel, A
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (03): : 316 - 320
  • [3] Clinically meaningful changes in functional status in patients with ankylosing spondylitis receiving etanercept (Enbrel®) or placebo
    Singh, A
    Wajdula, J
    Fatenejad, S
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S233 - S233
  • [4] Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept
    van Denderen, J. C.
    Blom, G. J.
    van der Horst-Bruinsma, I. E.
    Dijkmans, B. A. C.
    Nurmohamed, M. T.
    [J]. CLINICAL RHEUMATOLOGY, 2012, 31 (12) : 1677 - 1682
  • [5] WORK PRODUCTIVITY IN EMPLOYED PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH ETANERCEPT
    Boonen, A.
    Boone, C.
    Boon, T.
    Albert, A.
    Mielants, H.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 785 - 785
  • [6] Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept
    J. C. van Denderen
    G. J. Blom
    I. E. van der Horst-Bruinsma
    B. A. C. Dijkmans
    M. T. Nurmohamed
    [J]. Clinical Rheumatology, 2012, 31 : 1677 - 1682
  • [7] Sustained efficacy of etanercept (Enbrel®) in ankylosing spondylitis up to 18 months.
    Davis, JC
    van der Heijde, DM
    Braun, J
    Dougados, M
    Cush, JJ
    Clegg, DO
    Kivitz, AJ
    Inman, RD
    Whitmore, J
    Tsuji, W
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S611 - S611
  • [8] Radiographic results from a long-term multicenter trial of etanercept (ENBREL®) in patients with ankylosing spondylitis
    van der Horst-Bruinsma, I.
    Wanders, A.
    van der Heijde, D.
    Fatenejad, S.
    [J]. RHEUMATOLOGY, 2006, 45 : I5 - I5
  • [9] Response to pneumococcal vaccination in patients treated with etanercept (Enbrel®) trial.
    Mease, P
    Ritchlin, C
    Martin, R
    Baumgartner, S
    Burge, D
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S91 - S91
  • [10] WORK PRODUCTIVITY IN A COHORT OF EMPLOYED ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH ETANERCEPT
    Boonen, A.
    Boone, C.
    Albert, A.
    Mielants, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 289 - 289
12345